

Notice from the Executive Officer: Funding of Insulin Lispro under the Ontario Drug Benefit Program

January 25, 2021

Admelog® (insulin lispro) was approved by Health Canada as a biosimilar to Humalog® (insulin lispro). Biosimilars have similar efficacy and safety as originator biologics and present an opportunity to achieve better value for money for biologic drugs that will help to support long-term sustainability and accessibility of Ontario's public drug programs.

Effective with the December 2020 Ontario Drug Benefit (ODB) Formulary update, changes to funding of insulin lispro on the ODB Program were as follows:

For Admelog (insulin lispro):

- Admelog is listed on the ODB Formulary/Comparative Drug Index (Formulary) as a General Benefit.

Effective with the January 2021 Formulary update (effective date January 29, 2021), changes to the funding status of some Humalog products will be as follows:

- Some Humalog products will be listed on the Formulary as a Limited Use (LU) benefit for the following indication:
 - Reason for Use (RFU) Code 599: For the treatment of diabetes mellitus for only those patients currently established on Humalog therapy.

Please note that transition code RFU 279 will be activated for the affected Humalog products to help transition patients to the new RFU code and criteria. This transition code may be submitted for a claim for a period of three months after the change. It is expected that after three months all patients with a prescription for affected Humalog products have the correct RFU Code and meet the new clinical criteria. The transition code will be effective for 3 months and deactivated with the April 2021 Formulary update.

Details of the changes to the funding of Humalog will also be posted in the January 2021 Formulary update which can be found on the ministry's website at:

http://www.health.gov.on.ca/en/pro/programs/drugs/edition_43.aspx

To further inform healthcare providers and patients, we have also included a Frequently Asked Questions (FAQs) document for reference purposes.

Additional information:

For pharmacies:

Please call ODB Pharmacy Help Desk at: 1-800-668-6641

For all other health care providers and the public:

Please call ServiceOntario, Infoline at 1-866-532-3161 TTY 1-800-387-5559.
In Toronto, TTY 416-327-4282.